Navigating drug development with human multi-omics data and AI

Thore Buergel, PhD Co-founder and CEO, Pheiron

Speaker interview

“We are moving toward a world where the odds in drug discovery can be flipped” →

Over 50% of drug programs fail due to lack of efficacy. Despite decades of research, the etiology and pathophysiology of most diseases are still poorly understood. However, there has never been a better time to fix this: biomedical data on human genetics, -omics, and clinical outcomes is becoming available for millions of real-world individuals.

Pheiron’s platform integrates data from the world’s largest human biobanks, and combines human genetics with multi-modal AI, to accurately resolve disease pathology, and identify causal links between mechanisms, pathology and patient populations. In this talk, Thore explains how Pheiron’s human-level insights help identifying targets and de-risk translation.

Speaker bio

Thore Buergel, PhD

Co-founder and CEO, Pheiron

Thore studied Molecular Biotechnology and Bioinformatics at the University of Heidelberg, with research stays at Stanford University and the European Bioinformatics Institute, before completing his PhD at the Berlin Institute of Health. In 2023, Thore co-founded Pheiron, an AI-native biotech company innovating at the intersection of multi-omic disease understanding and genetics to advance next-generation therapeutics. Additionally, he is an Honorary Lecturer at the Institute of Cardiovascular Science of the University College London.